SUNSHINE: High-Dose Vitamin D Improved PFS in Colorectal Cancer
This video highlights results of the SUNSHINE study, which found that high-dose vitamin D added to standard treatment slowed disease progression in newly diagnosed metastatic colorectal cancer.
In this video, Kimmie Ng, MD, MPH, of the Dana-Farber Cancer Institute in Boston, highlights results of the SUNSHINE study, which found that high-dose vitamin D added to standard treatment slowed disease progression in newly diagnosed metastatic colorectal cancer.
Patients on the trial were treated with mFOLFOX6 plus bevacizumab and were randomized 1:1 to either a high-dose vitamin D therapy (8,000 IU/day for 2 weeks as a loading dose, followed by 4,000 IU/day) or low-dose vitamin D (400 IU/day).
Ng presented the results (abstract 3506) at the 2017 American Society of Clinical Oncology Annual Meeting, held June 2–6 in Chicago.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
![“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F9b290688648a249e516474c175a3c06309426d15-2950x1568.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.")
